DK2475649T3 - Indenonderivat og farmaceutisk sammensætning omfattende samme - Google Patents

Indenonderivat og farmaceutisk sammensætning omfattende samme

Info

Publication number
DK2475649T3
DK2475649T3 DK09849272.1T DK09849272T DK2475649T3 DK 2475649 T3 DK2475649 T3 DK 2475649T3 DK 09849272 T DK09849272 T DK 09849272T DK 2475649 T3 DK2475649 T3 DK 2475649T3
Authority
DK
Denmark
Prior art keywords
indenonderivative
pharmaceutical composition
composition comprehensive
comprehensive same
same
Prior art date
Application number
DK09849272.1T
Other languages
English (en)
Inventor
Jung Nyoung Heo
Myung-Ae Bae
Nack Jeong Kim
Sung Youn Chang
Namsook Kang
Sung Eun Yoo
Eun Sook Hwang
Original Assignee
Korea Res Inst Chem Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Chem Tech filed Critical Korea Res Inst Chem Tech
Application granted granted Critical
Publication of DK2475649T3 publication Critical patent/DK2475649T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C07D265/33—Two oxygen atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
DK09849272.1T 2009-09-11 2009-10-21 Indenonderivat og farmaceutisk sammensætning omfattende samme DK2475649T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090085954A KR101149529B1 (ko) 2009-09-11 2009-09-11 인덴온 유도체 및 이를 포함하는 약학적 조성물
PCT/KR2009/006085 WO2011030955A1 (en) 2009-09-11 2009-10-21 Indenone derivative and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
DK2475649T3 true DK2475649T3 (da) 2014-11-03

Family

ID=43732606

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09849272.1T DK2475649T3 (da) 2009-09-11 2009-10-21 Indenonderivat og farmaceutisk sammensætning omfattende samme

Country Status (22)

Country Link
US (1) US8877747B2 (da)
EP (1) EP2475649B1 (da)
JP (1) JP5705856B2 (da)
KR (1) KR101149529B1 (da)
CN (1) CN102482236B (da)
AU (1) AU2009352393B2 (da)
BR (1) BR112012005402B1 (da)
CA (1) CA2771799C (da)
CL (1) CL2012000609A1 (da)
CO (1) CO6511222A2 (da)
DK (1) DK2475649T3 (da)
EA (1) EA021353B1 (da)
ES (1) ES2521517T3 (da)
IL (1) IL218232A (da)
MX (1) MX2012002785A (da)
MY (1) MY164864A (da)
NZ (1) NZ598394A (da)
PL (1) PL2475649T3 (da)
PT (1) PT2475649E (da)
SG (1) SG178975A1 (da)
WO (1) WO2011030955A1 (da)
ZA (1) ZA201201727B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3135656T (lt) 2011-06-20 2019-04-25 H. Lundbeck A/S Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui
US20150148292A1 (en) 2012-07-09 2015-05-28 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
CN104370795B (zh) * 2014-10-15 2016-09-28 复旦大学 一种双靶向卵巢癌细胞微管蛋白及其周围血管的茚酮化合物及其制备方法与应用
CN105585566B (zh) * 2016-03-09 2017-12-29 河南师范大学 一种茚酮并咪唑并吡啶类化合物的合成方法
WO2017172368A1 (en) 2016-03-31 2017-10-05 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CN106117216B (zh) * 2016-08-26 2019-01-01 河南师范大学 一种常压合成6H-异吲哚[2,1-a]吲哚-6-酮类化合物的方法
KR101855087B1 (ko) * 2016-09-27 2018-05-04 충남대학교산학협력단 칼콘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 미토콘드리아의 산소 소모율 감소에 의해 야기되는 질환의 예방 또는 치료용 약학 조성물
KR101959636B1 (ko) * 2017-10-25 2019-07-04 경북대학교 산학협력단 인데엔 화합물을 유효성분으로 함유하는 골 재생 및 골 질환 예방 또는 치료용 조성물
CN107964009A (zh) * 2018-01-21 2018-04-27 吕迎春 一种2-吡啶衍生物取代的咪唑类化合物及其在防治骨质疏松药物中的应用
CN107892687B (zh) * 2018-01-21 2018-08-24 广东莱恩医药研究院有限公司 一种2-乙酸酯咪唑类化合物及其在防治骨质疏松药物中的应用
CN113056457B (zh) 2018-12-03 2025-06-20 H.隆德贝克有限公司 用于治疗cns疾病的前药
AU2023299045B2 (en) * 2022-06-29 2026-08-13 Amyloid Solution Inc. Novel indenone derivatives and uses thereof
CN119301119A (zh) * 2022-06-29 2025-01-10 淀粉样蛋白解决方案株式会社 新型茚酮衍生物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
AUPR283801A0 (en) 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
US6903238B2 (en) 2001-12-13 2005-06-07 Wyeth Substituted indenones as estrogenic agents
KR100592805B1 (ko) * 2004-04-13 2006-06-26 한국화학연구원 인덴 유도체 및 이의 제조방법
KR100595963B1 (ko) * 2004-04-13 2006-07-05 한국화학연구원 인덴 유도체 및 이의 제조방법
CN100371325C (zh) * 2004-07-23 2008-02-27 中国科学院上海药物研究所 一类茚并吲哚酮类化合物、其制备方法和用途
US9185909B2 (en) * 2007-09-17 2015-11-17 The Trustees Of Columbia University In The City Of New York Synthesis of resveratrol-based natural products

Also Published As

Publication number Publication date
BR112012005402B1 (pt) 2022-05-31
US20120214991A1 (en) 2012-08-23
MY164864A (en) 2018-01-30
BR112012005402A2 (pt) 2020-10-06
PL2475649T3 (pl) 2015-02-27
CO6511222A2 (es) 2012-08-31
KR20110028050A (ko) 2011-03-17
JP5705856B2 (ja) 2015-04-22
EP2475649B1 (en) 2014-08-13
WO2011030955A1 (en) 2011-03-17
IL218232A (en) 2015-11-30
MX2012002785A (es) 2012-04-11
AU2009352393A1 (en) 2012-03-22
CN102482236A (zh) 2012-05-30
CN102482236B (zh) 2015-01-28
EP2475649A4 (en) 2013-02-13
ZA201201727B (en) 2012-11-28
CA2771799A1 (en) 2011-03-17
HK1166633A1 (en) 2012-11-02
NZ598394A (en) 2013-07-26
AU2009352393B2 (en) 2015-12-24
EA201270410A1 (ru) 2012-08-30
CL2012000609A1 (es) 2012-09-14
SG178975A1 (en) 2012-04-27
JP2013504566A (ja) 2013-02-07
PT2475649E (pt) 2014-10-15
KR101149529B1 (ko) 2012-05-25
EA021353B1 (ru) 2015-05-29
EP2475649A1 (en) 2012-07-18
US8877747B2 (en) 2014-11-04
CA2771799C (en) 2016-11-08
ES2521517T3 (es) 2014-11-12
IL218232A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
DK3345625T3 (da) Farmaceutisk sammensætning og indgivelser deraf
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
DK2419732T3 (da) Prionfrie nanopartikelsammensætninger og fremgangsmåder
HRP20160579T1 (hr) Spoj indola i njegova farmaceutska upotreba
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BRPI1010079A2 (pt) composição e artigo
DK3460056T3 (da) Terapeutiske nukleasesammensætninger og fremgangsmåder
BRPI1011587A2 (pt) compostos e composições terapèuticas
DK3292874T3 (da) Anti-mesothelin-immunkonjugater og anvendelser deraf
DK2272339T3 (da) Fremgangsmåder og præparater til anvendelse med geldispensere
DK2504353T4 (da) Lipopeptidsammensætninger og tilsvarende fremgangsmåder
BRPI0924135A2 (pt) composição farmacêutica sólida compreendendo anlodipino e losartan
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
DK3278665T3 (da) Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
HUE065114T2 (hu) Monoklórtrifluorpropén vegyületek és készítmények és eljárások azok alkalmazásával
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
BR112012002247A2 (pt) composição e artigo
BRPI1015939A2 (pt) composição farmacêutica
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
BRPI1012539A2 (pt) composições farmacêuticas
DK2805746T3 (da) Alkylamido-forbindelser og anvendelser deraf
DK2154966T3 (da) Benzimidazoler og farmaceutiske sammensætninger deraf
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater